Results 131 to 140 of about 23,792 (240)

Mycochemical Diversity and Therapeutic Potential of Hymenochaetoid Fungi from Central Asia: Regional and Global Perspectives

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
Central Asia harbors a rich yet understudied assemblage of wood‐inhabiting Hymenochaetoid fungi. This review delivers the first comprehensive synthesis of 43 poroid species representing 18 genera documented across montane forests, steppes, and xeric habitats.
Yusufjon Gafforov, Milena Rašeta, Sylvie Rapior, Manzura Yarasheva, Oksana Mykchaylova, Rustamjon Allaberdiev, Şule İnci, Dilfuza Berdieva, Arshad Mehmood Abbasi, Shikhnazar Khodjaev, Dian‐Ming Hu, Weijun Yang, Abudujilili Abuduaini, Maria Letizia Taddei, Mengcen Wang, Islomjon Urinboev, Jiajia Chen   +16 more
wiley   +1 more source

Case Report on Hypoglycemia – Beyond Diet, Drugs and Diabetes

Medical Journal of Dr. D.Y. Patil Vidyapeeth
Hypoglycemia is a common presentation for various conditions presenting to the emergency department. After ruling out drugs as a cause, especially in nondiabetic individuals, classification to hyperinsulinemic or non-hyper insulinemic hypoglycemia is the
Krupa Dixit, Divya Prabhu, Vishwanath Krishnamurthy, PR Manjunath   +3 more
doaj   +1 more source

The Prebiotic and Techno‐Functional Potential of Microbial Exopolysaccharides for Human Health and Food Systems

Comprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 2, March 2026.
ABSTRACT Microbial exopolysaccharides (EPS) represent a diverse class of biopolymers holding considerable promise as functional food ingredients. This review analyzes the dual function of microbial EPS as a candidate for prebiotic agents and techno‐functional additives.
Md. Abdur Razzak, Hye Kim, Md. Ariful Haque, Min Ji Jang, Sehyeon Song, Anishka Talari, Lakshmi Devi Chittepu, Seockmo Ku   +7 more
wiley   +1 more source

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management, 2013
Anja Schweizer,1 James E Foley,2 Wolfgang Kothny,2 Bo Ahrén31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Department of Clinical Sciences, Lund University, Lund, SwedenAbstract: Due to ...
Schweizer A, Foley JE, Kothny W, Ahrén B   +3 more
doaj  

The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. [PDF]

Obesity (Silver Spring), 2023
Llewellyn DC, Logan Ellis H, Aylwin SJB, Oštarijaš E, Green S, Sheridan W, Chew NWS, le Roux CW, Miras AD, Patel AG, Vincent RP, Dimitriadis GK.   +11 more
europepmc   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

No Indices of Increased Type 2 Diabetes Risk in Individuals with Reactive Postprandial Hypoglycemia. [PDF]

Metabolites, 2022
Volčanšek Š, Rahne Perc U, Lunder M, Pongrac Barlovič D.   +3 more
europepmc   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1817-1825, March 2026.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Roux-en-Y Gastric Bypass Surgery Leading to Postprandial Hypoglycemia: A Case Report. [PDF]

Cureus, 2022
Coelho T, Freitas A, Carmona Alexandrino H, Pinto S.   +3 more
europepmc   +1 more source

CGM‐derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1836-1843, March 2026.
Abstract Aims To compare the associations of HbA1c and continuous glucose monitoring (CGM)‐derived average glucose with microvascular complications in adults with type 1 diabetes, and to assess the clinical utility and stability of metrics capturing glycation discordance. Materials and methods Observational assessment of 9023 paired measurements of CGM
Roland H. Stimson, Michael S. Crane, Anna R. Dover, Shareen Forbes, Rohana J. Wright, Marcus J. Lyall, Mark W. J. Strachan, Fraser W. Gibb   +7 more
wiley   +1 more source